Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$6.96 - $8.81 $16,008 - $20,263
-2,300 Reduced 15.28%
12,755 $89,000
Q1 2023

May 15, 2023

BUY
$7.94 - $11.84 $119,536 - $178,251
15,055 New
15,055 $125,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.39B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Point72 Middle East Fze Portfolio

Follow Point72 Middle East Fze and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Middle East Fze, based on Form 13F filings with the SEC.

News

Stay updated on Point72 Middle East Fze with notifications on news.